Cdc42 and Rac1 are necessary for autotaxin-induced tumor cell motility in A2058 melanoma cells  by Jung, In Duk et al.
Cdc42 and Rac1 are necessary for autotaxin-induced tumor cell motility
in A2058 melanoma cells
In Duk Junga, Jangsoon Leea, Seong Young Yuna, Chang Gyo Parka, Wahn Soo Choib,
Hyang Woo Leec, Oksoon H. Choid, Jeung Whan Hanc, Hoi Young Leea;
aCollege of Medicine, Konyang University, Nonsan 320-711, South Korea
bLaboratory of Molecular Immunology, NHLBI, National Institutes of Health, Bethesda, MD 20892-1760, USA
cCollege of Pharmacy, Sungkyunkwan University, Suwon 440-746, South Korea
dDepartment of Biochemistry, Meharry Medical College, Nashville, TN 37208, USA
Received 29 July 2002; revised 2 October 2002; accepted 20 October 2002
First published online 18 November 2002
Edited by Richard Marais
Abstract Autotaxin (ATX) is a strong motogen that can in-
crease invasiveness and angiogenesis. In the present study, we
investigated the signal transduction mechanism of ATX-induced
tumor cell motility. Unlike N19RhoA expressing cells, the cells
expressing N17Cdc42 or N17Rac1 showed reduced motility
against ATX. ATX activated Cdc42 and Rac1 and increased
complex formation between these small G proteins and p21-
activated kinase (PAK). Furthermore, ATX phosphorylated fo-
cal adhesion kinase (FAK) that was not shown in cells express-
ing dominant negative mutants of Cdc42 or Rac1. Collectively,
these data strongly indicate that Cdc42 and Rac1 are essential
for ATX-induced tumor cell motility in A2058 melanoma cells,
and that PAK and FAK might be also involved in the process.
1 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
Key words: Autotaxin; Rac1; Cdc42; Focal adhesion kinase
1. Introduction
Active tumor cell motility is involved in many stages of the
metastatic cascade, including the transition from in situ to
invasive carcinoma [1]. Dysregulation of motility plays an
important role in promoting invasion and metastasis [2]. Au-
totaxin [ATX; nucleotide-pyrophosphatase phosphodiester-
ase-2 (NPP-2)] is a 125-kDa autocrine motility factor which
stimulates motility of the same tumor cells that make the
factor [3]. ATX was initially isolated from A2058 human mel-
anoma cells and DNA sequence analysis revealed that ATX
was homologous to a family of exo/ecto NPPs that includes
the B cell activation marker, PC-1, and the neural di¡erentia-
tion antigen, B10 [4]. ATX contains two adjacent somatome-
din B regions, the loop region of an EF-hand, and a type I
phosphodiesterase catalytic site, and possesses 5P-nucleotide
pyrophosphatase/ATPase activities [5,6]. Recently, ATX was
reported to augment cellular characteristics necessary for tu-
mor aggressiveness [7]. ATX expression in ras-transformed
NIH3T3 cells showed ampli¢ed tumorigenesis and metastatic
potential compared to ras-transformed control. Furthermore,
ATX was reported as an angiogenic factor that stimulates
HUVECs grown on Matrigel to form tubules [8]. Accumulat-
ing evidence suggests that various intracellular signaling mol-
ecules such as phosphatidylinositide 3-kinase (PI3K), phos-
pholipase CQ, mitogen-activated protein kinase, and protein
kinase C were di¡erentially involved in the stimulation of
motility, depending on kinds of chemoattractants and cellular
systems [2]. Small G proteins of the Rho family also have
various e¡ects on the actin cytoskeleton and focal adhesions
that may actively participate in chemoattractant-induced mo-
tility. While Cdc42 controls the formation of ¢lopodia, Rac1
and RhoA are involved in the formation of lamellipodia and
actin stress ¢bers, respectively [9^11]. Activated Cdc42 and
Rac1 bind and activate p21-activated kinase (PAK) which in
turn targets cytoskeletal movements [12].
Focal adhesion kinase (FAK) is a cytoplasmic protein-ty-
rosine kinase that localizes to focal adhesions [13]. FAK can
be phosphorylated by growth factors and during formation of
focal adhesions and spreading [14]. Activated FAK in turn
recruits other proteins, including paxillin, p130Cas, vinculin,
and talin in focal adhesions. These protein complexes anchor
the actin cytoskeleton and provide structural integrity to cells
[15].
Although ATX has been demonstrated to stimulate tumor
cell motility and to augment characteristics necessary for tu-
mor aggressiveness, little is known about the intracellular sig-
naling mechanism of ATX except its link to G protein-
coupled unknown receptor [16]. Recently, we have shown
that G protein-coupled PI3KQ is involved in ATX-induced
tumor cell motility stimulation [17]. In the present study, we
continued to investigate the cellular signal transduction mech-
anism of ATX-induced tumor cell motility and found that
Cdc42 and Rac1 mediate in ATX-induced motility of A2058
melanoma cells.
2. Materials and methods
2.1. Reagents
C3 exoenzyme and pertussis toxin (PTx) were purchased from Cal-
biochem (San Diego, CA, USA). Anti-Rac1, anti-Cdc42, anti-FAK,
and anti-phosphotyrosine (PY20) antibodies were purchased from
Transduction Laboratories (Lexington, KY, USA). Anti-PAK1 was
purchased from Santa Cruz Technology (Santa Cruz, CA, USA).
Y27632 was from Tocris (Bristol, UK), and Sepharose 4B was from
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Amersham Bioscience (Seoul, Korea). LY294002, Wortmannin, and
MBP were from Sigma (Seoul, Korea). All reagents from commercial
sources were of analytical grade.
2.2. Cell culture
The human melanoma cell line A2058, originally isolated from To-
daro et al.[18], was maintained as described previously [19]. The cells
were maintained at 37‡C in Dulbecco’s modi¢ed Eagle’s medium
(DMEM) with 10% fetal bovine serum (complete medium) in a hu-
midi¢ed 5% CO2. For analysis of ATX-induced signals, cells in ex-
ponential growth were washed extensively to remove growth factors
and resuspended in serum-free media (basal media) for 16 h to induce
maximum synchronization.
2.3. Expression plasmid and transfection
Vectors (pEBG) expressing the catalytically inactive mutants
N17Rac1 and N17Cdc42 were obtained from Dr. John Blenis of
Harvard Medical School. N19RhoA in pcDNA3 was from Dr.
Seung-Kil Park of Chungnam University, Korea, and GST-P21-bind-
ing domain (GST-PBD) of PAK was from Dr. Dongeun Park of
Seoul University, Korea. A2058 melanoma cells were transiently
transfected with each vector using the SuperFect1 transfection system
(Qiagen) as described previously in detail [17]. Cells were washed with
phosphate-bu¡ered saline (PBS) and grown in complete medium for
48 h before cell motility, immunoprecipitation, and immunoblotting
analysis.
2.4. Puri¢cation of recombinant ATX (rATX)
Teratocarcinoma ATX cDNA and its T210A mutant form
(A210ATX) were subcloned into the plasmid vector pcDNA3 (Invi-
trogen) and then transiently transfected into Cos-1 cells using the
DEAE^dextran method [20]. A210ATX mutant is an ATX mutant
without phosphodiesterase and tumor cell motility-stimulating activ-
ities [21]. Control for these experiments was Cos-1 cells that had been
transfected with empty pcDNA3 vector. After overnight recovery in
complete medium, DMEM containing 0.1 mg/ml bovine serum albu-
min was added to the cells, harvested after 48 h, and concentrated.
The concentrated supernatants from ATX-, A210ATX-transfected,
and control Cos-1 cells were partially puri¢ed by lectin a⁄nity chro-
matography with concanavalin A^agarose (Vector Laboratories) as
described previously in detail [21].
2.5. Immunoprecipitation and immunoblotting
Cell lysates were prepared with lysis bu¡er (50 mM Tris^HCl, pH
7.4, 1% Nonidet P-40, 150 mM NaCl, 1 mM EDTA, 1 mM phenyl-
methylsulfonyl £uoride, 1 Wg/ml aprotinin, 1 Wg/ml leupeptin, 1 mM
sodium orthovanadate, and 1 mM NaF). FAK and PAK were pre-
cipitated from the cell lysates (400 Wg of total protein) with speci¢c
antibodies for 3 h at 4‡C. Protein^antibody complexes were collected
with protein A^Sepharose beads for 3 h at 4‡C. The precipitates were
washed three times with ice-cold lysis bu¡er, resolved by 7.5% SDS^
PAGE. Tyrosine phosphorylation and protein levels of FAK, PAK,
Cdc42, and Rac1 were assessed by immunoblotting with anti-phos-
photyrosine (PY20) or the speci¢c antibodies as used for precipita-
tions. Immunolabeling was detected by ECL (Amersham Life Science)
according to the manufacturer’s instructions.
2.6. Small G protein pull-down assays
The Cdc42-GTP and Rac1-GTP pull-down assay was modi¢ed
from Benard et al. [22]. In brief, Cells were washed with ice-cold
PBS and lysed with lysis bu¡er (150 mM NaCl, 0.8 mM MgCl2,
5 mM EGTA, 1% NP-40, 50 mM HEPES, pH 7.5, 1 mM PMSF,
10 Wg/ml leupeptin, and 10 Wg/ml aprotinin). After centrifuged at
14 000Ug for 5 min, 20 Wl of a 50% slurry of GST-PAK-PBD gluta-
thione-Sepharose 4B added to cell lysate and incubated for 45 min at
4‡C. Proteins bound to beads were washed with 50 mM Tris^HCl, pH
7.2, 1% Triton X-100, 150 mM NaCl, 10 mM MgCl2, 1 mM PMSF,
10 Wg/ml leupeptin, 10 Wg/ml aprotinin and eluted in Laemmli sample
bu¡er. Proteins were analyzed by Western blotting using antibodies
against Cdc42 or Rac1.
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Fig. 1. Cdc42 and Rac1 are involved in ATX-induced tumor cell
motility. A: A2058 melanoma cells were transiently transfected with
each of N17Rac1, N17Cdc42, N19RhoA, and the corresponding
control vectors. B: After preincubation with various concentrations
of RhoA or Rho kinase inhibitors, cells were further incubated with
or without 250 ng/ml ATX. Motility was analyzed by using modi-
¢ed Boyden chamber assay. Data shown are the densitometric val-
ues with the meanTS.D. of three separate experiments, and motility
assay was carried out in triplicate. *P6 0.05 in comparison with
vector-transfected cells.
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2.7. Cell motility assays
Motility assays were performed in triplicate using a 48-well micro-
chemotaxis chamber for 4 h as described previously in detail [16].
Cells were harvested using a trypsin/EDTA solution and resuspended
in DMEM with 1 mg/ml bovine serum albumin. The bottom wells
were ¢lled with varying concentrations of puri¢ed ATX and
A210ATX mutant. Gelatin-coated polyvinyl pyrrolidine-free polycar-
bonate ¢lters with 8 Wm pores membranes (Neuroprobe) used in these
modi¢ed Boyden chambers were ¢xed and stained using Di¡-Quik
reagents (American Scienti¢c Products). Chemotaxis was quanti¢ed
densitometrically using EagleSight Software v. 3.2 (Stratagene) for
data analysis as described previously [17].
2.8. Statistical analysis
Results are expressed as the meanTS.D., and an analysis was done
by one-way Student’s t-test. P-values less than 0.05 were considered
statistically signi¢cant.
3. Results and discussion
ATX has been shown to augment the cellular characteristics
necessary for tumor invasiveness [7] and angiogenesis [8].
However, little is known about the signaling pathway of
ATX-induced tumor cell motility. Recently, we have shown
that the G protein-coupled isoform of PI3K (PI3KQ) is neces-
sary for ATX-induced tumor cell motility in A2058 melanoma
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Fig. 2. ATX induces Rac1-PAK and Cdc42-PAK complex formation. A: A2058 melanoma cells were serum-deprived and then treated with ve-
hicle, ATX, and A210ATX for 30 min. B: Cells were treated with or without each reagents (0.2 Wg/ml PTx, 90 min; 0.5 WM wortmannin, 30
min; 10 WM LY294002, 30 min) before incubating with ATX. Cell lysates were immunoprecipitated (IP) with an anti-PAK antibody following
by anti-Rac1 or anti-Cdc42 immunoblotting (IB). Data shown are representative of three experiments with similar results.
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Fig. 3. ATX activates Cdc42 and Rac1. A2058 melanoma cells were
serum-deprived and treated with or without 10 WM LY294002 (LY)
for 30 min before incubating with ATX (0.25 Wg/ml) for 30 min.
Cellular extracts were incubated with GST-PAK-PBD beads. The
bound proteins (Cdc42-GTP or Rac1-GTP) were analyzed by West-
ern blot analysis using speci¢c anti-Cdc42 and Rac1 antibodies.
Data shown are representative of four experiments with similar re-
sults.
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cells [17]. ATX increased PI3KQ activity that was abolished by
pretreatment of A2058 melanoma cells with PTx or PI3K
inhibitors. In the present study, we investigated the involve-
ment of Rho family GTPases in ATX-induced tumor cell
motility since Cdc42, Rac1, and RhoA located downstream
of PI3K have been recognized as key regulators for cell
migration [23]. ATX-induced cell motility was measured
in A2058 melanoma cells transfected with pEBG vector,
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Fig. 4. FAK is phosphorylated by ATX. A: A2058 melanoma cells were serum-deprived and then treated with control, ATX, and A210ATX
for 30 min. B: Cells were treated with or without each reagent (0.2 Wg/ml PTx, 90 min; 0.5 WM wortmannin, 30 min; 10 WM LY294002, 30
min) before ATX treatment. C: After transfection with each of N17Rac1, N17Cdc42, N19RhoA, and the corresponding control vectors, cells
were incubated with either control or ATX for 30 min. Cell lysates were immunoprecipitated (IP) with an anti-FAK antibody and followed by
immunoblotting (IB) with anti-phosphotyrosine antibody (PY20). Data shown are representative of four experiments with similar results.
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pcDNA3 vector, and inactive mutants of Rac1 (N17Rac1),
Cdc42 (N17Cdc42), and RhoA (N19RhoA). As shown in
Fig. 1A, overexpression of dominant negative Rac1 or
Cdc42 completely or partially inhibited ATX-induced motil-
ity, respectively. In contrast, overexpression of dominant neg-
ative RhoA had no e¡ects on ATX-induced cell motility.
Consistent with the result, C3 exoenzyme or Y27632, which
inhibits RhoA and Rho kinase, respectively, did not inhibit
cell motility by ATX (Fig. 1B), con¢rming that RhoA was not
involved in the signal transduction of ATX-induced tumor cell
motility. These results suggested the possible involvement of
Cdc42 and Rac1, but not RhoA, in ATX-induced tumor cell
motility. These observations are in accordance with Cdc42/
Rac dependent- and RhoA independent-enhancement of cell
motility by Vav3 [24] and VEGF [25]. One of the well-char-
acterized downstream target molecules of Rac/Cdc42 is PAK
[26]. By direct interaction of its p21-binding domain with
GTP-bound active Cdc42 or Rac, group I PAKs (PAK1^3)
undergoes a conformational change that allows its autophos-
phorylation and activation [27]. To test the e¡ects of ATX on
PAK1, A2058 melanoma cells were treated with increasing
concentrations of ATX and A210ATX mutant. As shown in
Fig. 2, ATX increased association of Rac1 and Cdc42 with
PAK in a dose-dependent manner, while control or A210ATX
did not. This complex formation was completely blocked by
PTx or PI3K inhibitors, wortmannin or LY294002, (Fig. 2B),
suggesting that Rac1 and PAK were located downstream of
PI3KQ in ATX-induced tumor cell motility.
To verify that activated Rac1 and Cdc42 form a complex
with PAK, direct pull-down experiments were performed by
measuring the binding of GTP-bound GTPase to the p21-
binding domain of PAK1 fused to glutathione S-transferase
(GST-PBD) [28]. As shown in Fig. 3, ATX increased the levels
of Cdc42-GTP and Rac1-GTP that were inhibited by the pre-
incubation with LY294002, con¢rming that ATX activates
Cdc42 and Rac1 via the activation of PI3KQ.
FAK is a non-receptor protein-tyrosine kinase that is local-
ized at focal contact sites and plays a critical role in control-
ling cell migration [29,30]. An increased level of FAK expres-
sion is highly correlated with the invasion potential of human
tumors [31]. FAK phosphorylation was increased by increas-
ing concentrations of ATX but not by vector control or
A210ATX mutant (Fig. 4A). ATX-induced phosphorylation
of FAK was completely inhibited by PTx or PI3K inhibitors
(Fig. 4B). In addition, FAK phosphorylation was also inhib-
ited by dominant negative mutants of Rac1 and Cdc42 but
not by RhoA (Fig. 4C). The data suggest that FAK phos-
phorylation is the consequence of ATX-induced activation of
PI3K, Rac1, and Cdc42. At present, we do not have direct
evidence showing that FAK phosphorylation is necessary for
ATX-induced cell motility. However, one might be able to
speculate that FAK phosphorylation could be involved in
ATX-induced cell motility because inhibition of the same up-
stream molecules inhibits both FAK phosphorylation and cell
motility. Furthermore, A210, an ATX mutant without motil-
ity-stimulating activity, did not phosphorylate FAK phos-
phorylation.
Recently, ATX was reported to have a lysophospholipase D
(lysoPLD) activity [32]. LysoPLD catalyzes the conversion
of lysophosphatidylcholine to lysophosphatidic acid (LPA),
which mediates multiple biological functions, including cyto-
skeletal reorganization, chemotaxis, and cell growth through
activation of speci¢c G protein-coupled receptors [33,34]. It is
very possible that ATX mediates its biological e¡ects through
the generation of LPA as suggested [32]. Our ¢ndings, which
demonstrate that ATX-induced cell motility is sensitive to
PTx treatment and dependent on the activation of Rac1 and
Cdc42, appear to agree with the signaling pathways demon-
strated with activation of Edg receptors by LPA [35]. LPA
was also shown to increase phosphorylation of FAK in hu-
man osteosarcoma cells [36] and in preosteoblastic cells [37].
Furthermore, RhoA was demonstrated to activate FAK phos-
phorylation [38], and ROCK inhibitor Y27632 suppressed
LPA-induced tyrosine phosphorylation of FAK [39]. Our
data showed that RhoA was not involved in ATX-induced
FAK phosphorylation in A2058 melanoma cells (Fig. 4C).
It is possible that di¡erent small G proteins are involved in
ATX/LPA-induced cell motility in di¡erent cell types.
The present study provides the evidence that ATX activates
small G proteins and induces Cdc42/Rac1-PAK1 complex for-
mation. Furthermore, ATX increased the phosphorylation of
FAK which is located downstream of PI3K and small G
proteins in ATX-induced tumor cell motility. At present we
do not know how Cdc42 and Rac1 regulate FAK phosphor-
ylation. Since FAK was coimmunoprecipitated with both
NCK and PAK in vascular endothelial growth factor-acti-
vated endothelial cell [40], NCK might be a mediator that
connects between PAK and FAK in ATX-induced tumor
cell motility.
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